Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter clinical study

  • Takahiro WakasakiI,
  • Tomomi Manako,
  • Ryuji YasumatsuI,
  • Hirotaka Hara,
  • Satoshi Toh,
  • Muneyuki Masuda,
  • Moriyasu YamauchiID,
  • Yuichiro Kuratomi,
  • Emi Nishimura,
  • Toranoshin Takeuchi,
  • Mioko Matsuo,
  • Rina Jiromaru,
  • Kazuki Hashimoto,
  • Noritaka Komune,
  • Takashi Nakagawa
  • Article
  • Metrics
  • Comments
  • Media Coverage

There are errors in the author affiliations. The correct affiliations are as follows:

Takahiro Wakasaki 1, 2, Tomomi Manako 1, Ryuji Yasumatsu 1,3 *, Hirotaka Hara 4, Satoshi Toh 4, Muneyuki Masuda 4, Moriyasu Yamauchi 5, Yuichiro Kuratomi 5, Emi Nishimura 6, Toranoshin Takeuchi 6, Mioko Matsuo 1, Rina Jiromaru 1, Kazuki Hashimoto 1, Noritaka Komune 1, and Takashi Nakagawa 1

1 Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812–8582, Japan 2 Department of Otorhinolaryngology, Japanese Red Cross Fukuoka Hospital, Fukuoka, 815–8555, Japan. 3 Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Kindai University, Osaka 589–8511, Japan. 4 Department of Head and Neck Surgery, National Hospital Organization, Kyushu Cancer Center, Fukuoka 812–8582, Japan 5 Department of Otolaryngology, Head and Neck Surgery, Saga University Hospital, Saga, 849–8501, Japan 6 Department of Otorhinolaryngology, Kitakyushu Municipal Medical Center, Kitakyushu 802–8561, Japan

Reference

  1. 1. Wakasaki T, Manako T, Yasumatsu R, Hara H, Toh S, Masuda M, Yamauchi M, Kuratomi Y, Nishimura E, Takeuchi T, Matsuo M, Jiromaru R, Hashimoto K, Komune N, Nakagawa T. Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study. PLoS One. 2022 Jul 28;17(7):e0271907. pmid:35901098; PMCID: PMC9333293.

Citation: WakasakiI T, Manako T, YasumatsuI R, Hara H, Toh S, Masuda M, et al. (2024) Correction: Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter clinical study. PLoS ONE 19(5): e0303720. https://doi.org/10.1371/journal.pone.0303720

Published: May 9, 2024

Copyright: © 2024 WakasakiI et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.